Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 4/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4684742 | 1.00 | PSMB1 (0.53) | PSMB1PSMB5KDM4EPSMB2MEN1 | |
| SCHEMBL3815002 | 0.99 | PSMB1 (0.51) | PSMB1PSMB5KDM4EPSMB2MEN1 | |
| SCHEMBL3376479 | 0.92 | HRH2 (0.48) | KDM4EMEN1KMT2ALTA4HALDH1A1 | |
| SCHEMBL3376486 | 0.92 | HRH2 (0.48) | KDM4EMEN1KMT2ALTA4HALDH1A1 | |
| SCHEMBL3376481 | 0.92 | HRH2 (0.48) | KDM4EMEN1KMT2ALTA4HALDH1A1 | |
| SCHEMBL3379563 | 0.90 | ALDH1A1 (0.53) | KDM4EMEN1KMT2ALTA4HHRH3 | |
| SCHEMBL3379568 | 0.90 | ALDH1A1 (0.53) | KDM4EMEN1KMT2ALTA4HHRH3 | |
| SCHEMBL3379566 | 0.90 | ALDH1A1 (0.53) | KDM4EMEN1KMT2ALTA4HHRH3 | |
| SCHEMBL5227540 | 0.85 | KDM4E (0.56) | PSMB1PSMB5KDM4EPSMB2MEN1 | |
| SCHEMBL31737696 | 0.83 | HRH2 (0.48) | KDM4ELTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427635-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1781649-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | EP | disclosed |
| US-20060041146-A1 | Substituted hydantoins | HOFFMANN-LA ROCHE AG | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041146-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | PSMB1 4584/4885PSMB5 4162/4885KDM4E 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.